Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KLRA Kailera Therapeutics, Inc.

交易中 07-10 11:41:00 EDT

20.26

-0.75

-3.59%

最高22.05	最低20.12	成交量12.39万
今开21.00	昨收21.01	日振幅9.19%
总市值26.24亿	流通市值9.10亿	总股本1.30亿
成交额256.91万	换手率0.28%	流通股本4,492万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":20.255,"timestamp":1783698052416,"preClose":21.01,"halted":0,"volume":123874,"delay":0,"changeRate":-0.03593526891956223,"floatShares":44921899,"shares":129537300,"eps":-1.204378,"marketStatus":"交易中","change":-0.755,"latestTime":"07-10 11:41:00 EDT","open":21,"high":22.05,"low":20.12,"amount":2569117.8973580003,"amplitude":0.091861,"askPrice":20.38,"askSize":200,"bidPrice":20.19,"bidSize":98,"shortable":3,"etf":0,"ttmEps":-1.204378,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783713600000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":21.01,"preHourTrading":{"tag":"盘前","latestPrice":21.99,"preClose":21.01,"latestTime":"07:06 EDT","volume":31,"amount":656.970011,"timestamp":1783681563590,"change":0.98,"changeRate":0.046644,"amplitude":0.047063},"postHourTrading":{"tag":"盘后","latestPrice":21.01,"preClose":21.01,"latestTime":"19:26 EDT","volume":3414,"amount":71736.2,"timestamp":1783639567190,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.453238},"requestUrl":"/m/hq/s/KLRA","defaultTab":"news","newsList":[{"id":"1152571405","title":"Kailera Therapeutics减肥药在华三期试验达主要终点，盘前股价上涨1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152571405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152571405?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:37","pubTimestamp":1783424267,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics, Inc. (KLRA)的股价在盘前交易中上涨了1.9%。此前，该公司宣布其研发的一款减肥药物在中国进行的后期临床试验中达到了主要终点。这一积极进展增强了市场对其药物开发前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174709421","title":"Kailera Therapeutics公布Hengrui Pharma口服小分子GLP-1受体激动剂HRS-7535/KAI-7535两项III期临床试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1174709421","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174709421?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422302,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics公司宣布，其合作伙伴Hengrui Pharma研发的口服小分子GLP-1受体激动剂HRS-7535在两项III期临床试验中取得了积极的顶线结果。作为一款口服制剂，HRS-7535/KAI-7535若成功上市，有望为患者提供比现有注射疗法更为便捷的用药选择。GLP-1受体激动剂是当前代谢疾病治疗领域的热点，主要应用于2型糖尿病和肥胖症的管理。此次公布的积极数据，进一步验证了该靶点及口服给药途径的可行性，为相关疾病的治疗格局增添了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134385043","title":"Kailera Therapeutics公司推进Kai-7535在肥胖或超重人群中的全球II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1134385043","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134385043?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:04","pubTimestamp":1783422285,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics公司正推动其候选药物Kai-7535，在全球范围内针对肥胖或超重人群展开一项关键的II期临床试验。这项研究标志着该公司在代谢疾病治疗领域迈出了重要一步，旨在评估该药物的安全性与有效性。随着全球肥胖问题日益严峻，此类创新疗法的进展备受关注，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141920352","title":"Kailera Therapeutics 公布 HRS-7535 三期与 HRS-4729 一期试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141920352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141920352?lang=zh_cn&edition=full","pubTime":"2026-05-27 04:08","pubTimestamp":1779826103,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 宣布，其候选药物 HRS-7535 的三期临床试验以及 HRS-4729 的一期临床试验均取得了积极的顶线数据结果。这一进展标志着公司在相关治疗领域的研发取得了重要突破，为后续的临床开发与监管申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195378546","title":"Kailera Therapeutics获Leerink Partners首次覆盖，给予“跑赢大盘”评级，目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195378546","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195378546?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:11","pubTimestamp":1778580703,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，对生物制药公司Kailera Therapeutics启动研究覆盖。该机构给予该公司股票“跑赢大盘”的初始评级，并设定了每股36美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766952","title":"减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766952","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766952?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:45","pubTimestamp":1776584754,"startTime":"0","endTime":"0","summary":"减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33340/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["QQQJ","QYLG","LU2580892862.HKD","SQQQ","LU2495084118.USD","LU2328871848.SGD","LU2580892789.USD","LU1146622755.USD","MNQmain","LU2289578879.USD","BK0012","LU1997245177.USD","BK0028","QLD","IYW","QDTE","LU0359201885.HKD","BK0060","FTEC","QQQE","QQQM","GPIQ","BK4007","LU1064131003.USD","BK0188","PSQ","LU0359201612.USD","LU2543165471.USD","01276","LU0359202008.SGD","QID","LU1023057109.AUD","LU1064130708.USD","LU2097828714.EUR","TQQQ","BK1191","KLRA","JEPQ","LU1655091616.SGD","LU2097828474.EUR","LU1781817850.SGD","LU2488822045.USD","LU2097828631.EUR","BK0196","LU2097828557.USD","600276","LU1820825898.SGD","NVIW.SI","QQQ","QQQA","LU1328615791.USD","TQQY","ONEQ","LU1997244956.HKD","LU0405327494.USD","NQmain","LU1255011170.USD","LU0405327148.USD","BK0239","BK0183","BK1147","LU1997245094.SGD","LU2148510915.USD","LU1580142542.USD","LU1969619763.USD","LU2097828805.USD","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136289592","title":"异动解读 | 凯莱拉治疗公司盘中大涨62.5%，受益于纳斯达克成功上市及减肥药市场广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1136289592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136289592?lang=zh_cn&edition=full","pubTime":"2026-04-18 01:27","pubTimestamp":1776446849,"startTime":"0","endTime":"0","summary":"凯莱拉治疗公司今日盘中股价大幅上涨62.50%，引起了市场的广泛关注。此次股价大涨与公司成功登陆纳斯达克密切相关。消息显示，凯莱拉治疗公司首次公开募股以每股16美元的价格发行，而市场预期其开盘价将达到32美元，远高于发行价，这反映了投资者对公司的高度认可和强烈兴趣。凯莱拉治疗公司的主要候选产品ribupatide作为一种每周注射一次的GLP-1药物，目前正处于后期试验阶段，这进一步增强了市场对其未来商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628578522?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场，开盘暴涨超50%，报24.1美元，IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年，是一家处于临床后期的生物科技公司，正在开发四种基于GLP-1的减肥药物，其中包括一款每周注射一次的药物和一款每日口服一次的药片，目前均已进入后期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KLRA","BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221198","title":"募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221198","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221198?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:33","pubTimestamp":1776396818,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于肥胖症治疗的临床阶段生物科技公司Kailera Therapeutics Inc.通过扩大首次公开发行规模，成功募资6.25亿美元，创下2021年以来美国生物科技领域规模最大的IPO纪录。根据周四发布的一份声明，Kailera以每股16美元的价格出售了约3900万股股票。包括贝恩资本旗下Bain Capital Private Equity、Bain Capital Life Sciences和卡塔尔投资局在内的现有股东已表示，有意按IPO价格合计购买最多2.25亿美元的公司股票。此次IPO之前，Kailera已于去年10月通过B轮融资募资6亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MNQmain","BK1147","TQQY","QQQA","QQQM","QLD","ONEQ","TQQQ","FTEC","BK4539","QYLG","QQQE","GPIQ","QID","QQQJ","KLRA","SQQQ","QQQY","BK4007","JEPQ","BK4139","NVIW.SI","QQQ","IYW","PSQ","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627741817","title":"减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2627741817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627741817?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:19","pubTimestamp":1776151188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics于周一公布其首次公开募股条款。根据计划，Kailera 预计将于本周四晚间完成最终定价，并于次日在纳斯达克交易所挂牌交易。其核心候选药物ribupatide目前正在全球开展III期临床试验，这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。Kailera Therapeutics成立于2024年，计划在纳斯达克上市，股票代码为KLRA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","BK4007","QQQY","FTEC","QDTE","QQQJ","IYW","JEPQ","MNQmain","QQQE","ONEQ","BK4139","GPIQ","PSQ","SQQQ","TQQQ","QQQA","QLD","QQQ","NVIW.SI","QYLG","TQQY","BK4539","QID","KLRA","QQQM"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":-0.0446},{"period":"1month","weight":0.0698},{"period":"3month","weight":0.3131},{"period":"ytd","weight":0.3131}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司，致力于通过推进多元化的研发管线，引领肥胖症治疗的新时代。目前，该公司正在快速推进四款处于临床阶段的候选产品，这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。","exchange":"NASDAQ","name":"Kailera Therapeutics, Inc.","nameEN":"Kailera Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kailera Therapeutics, Inc.,KLRA,Kailera Therapeutics, Inc.股票,Kailera Therapeutics, Inc.股票老虎,Kailera Therapeutics, Inc.股票老虎国际,Kailera Therapeutics, Inc.行情,Kailera Therapeutics, Inc.股票行情,Kailera Therapeutics, Inc.股价,Kailera Therapeutics, Inc.股市,Kailera Therapeutics, Inc.股票价格,Kailera Therapeutics, Inc.股票交易,Kailera Therapeutics, Inc.股票购买,Kailera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}